Instruments for Assessing Chemotherapy-Induced Peripheral Neuropathy: A Review of the Literature

Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of many commonly used chemotherapeutic agents (Hershman et al., 2014; Pachman, Barton, Watson, & Loprinzi, 2011). The reported incidence of CIPN ranges from 0%–70% in patients receiving chemotherapy (Pachman et al., 2011). Common symptoms of CIPN are sensory neuropathies, including paresthesia and pain. These symptoms may resolve completely but, in many instances, are only partially reversible, leading to decreased functional status and disability (Pachman et al., 2011).